Pharmacokinetics of etanidazole (SR-2508) in bladder and cervical cancer: Evidence of diffusion from urine

Following an IV infusion of 2.0 g/m 2 of Etanidazole, the mean tumor concentration 40 min after injection was 126 μg/g in bladder cancer and 65 μg/g in cervical cancer. The tumor/plasma concentration ratio was 1.88 in bladder and 0.85 in cervical cancer. This high tumor concentration in bladder canc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Int. J. Radiat. Oncol., Biol. Phys.; (United States) Biol. Phys.; (United States), 1989-04, Vol.16 (4), p.1083-1084
Hauptverfasser:	Awwad, Hassan K., El Badawy, Samy, Abd El Baki, Hoda, Zaghloul, Mohammed, Osman, Abd El Moneim, Akouh, Hany, Fairchild, Karen
Format:	Artikel
Sprache:	eng
Schlagworte:	550603 - Medicine- External Radiation in Therapy- (1980-) 560151 - Radiation Effects on Animals- Man BLADDER Bladder cancer BODY Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - urine Diffusion DISEASES DRUGS Etanidazole EVALUATION Female FEMALE GENITALS Humans NEOPLASMS Nitroimidazoles - pharmacokinetics Nitroimidazoles - urine ORGANS RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT Radiation-Sensitizing Agents - pharmacokinetics Radiation-Sensitizing Agents - urine RADIOLOGY AND NUCLEAR MEDICINE RADIOSENSITIZERS SR-2508 Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - urine URINARY TRACT Uterine Cervical Neoplasms - metabolism Uterine Cervical Neoplasms - urine UTERUS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Following an IV infusion of 2.0 g/m 2 of Etanidazole, the mean tumor concentration 40 min after injection was 126 μg/g in bladder cancer and 65 μg/g in cervical cancer. The tumor/plasma concentration ratio was 1.88 in bladder and 0.85 in cervical cancer. This high tumor concentration in bladder cancer could be accounted for by diffusion from a highly concentrated urine. This renders bladder cancer a suitable clinical model for testing this sensitizer.
ISSN:	0360-3016 1879-355X
DOI:	10.1016/0360-3016(89)90921-8